Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable. Unfortunately, the reported benefit probably isn't strong enough to consider the still-experimental treatment a potential market leader.Amgen's anti-obesity program might not be firing on all cylinders, but that doesn't necessarily make it a bad investment. Here's a look under the hood to see if now is a good time to buy, sell, or hold the biotech stock.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool